Clinical Trial Update: Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing immunogenicity, reactogenicity, and safety of GNG-DE versus a reference drug for meningococcal disease. The study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• GNG-DE

Snippet

Sponsor: NPO Petrovax | Conditions: Infections, Meningococcal | Phase 3 | Status: RECRUITING